Exploring how to improve drug delivery to cancer cells using barcoding technology
Understanding drug delivery through an integrated barcoding approach
This study is looking at how to better deliver tiny particles that can help treat cancer, especially tough types like ovarian cancer, by figuring out how they interact with tumors and what makes them work better, so we can create more effective treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10894315 on NIH RePORTER |
What this research studies
This research investigates the challenges of delivering nanoparticles effectively to cancer cells, particularly in lethal cancers like ovarian cancer. By utilizing a chemical barcoding approach, the study aims to analyze how different nanoparticles interact with tumors and identify genetic features that enhance their uptake. This high-throughput analysis will help researchers understand the factors that contribute to successful drug delivery, ultimately leading to more effective cancer treatments. The goal is to improve the targeting and accumulation of nanoparticles in tumors, which is currently very low.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer or other lethal cancers that may benefit from improved drug delivery methods.
Not a fit: Patients with non-cancerous conditions or those not undergoing treatment for cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that significantly improve patient outcomes.
How similar studies have performed: Other research has shown promise in improving drug delivery through innovative approaches, but this specific barcoding method is relatively novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Boehnke, Natalie — University of Minnesota
- Study coordinator: Boehnke, Natalie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.